Contribute Try STAT+ Today

Pharma

Taking stock of the drug industry, from the lab to the medicine chest. For a weekly update, sign up for our free Pharmalot newsletter. And subscribe to STAT+ for exclusive coverage and analysis of the pharma industry — from drug pipelines to boardroom shakeups.

Pharmalot By Ed Silverman

Dutch advisory group says Zolgensma shouldn’t be covered unless Novartis halves price

Zorginstituut Nederland argues that the research so far does not justify the high price that Novartis is asking for its gene therapy.

Pharmalot By Ed Silverman

Pharmalittle: Novavax sees delay in seeking emergency use of its Covid-19 shot; AstraZeneca CEO’s pay causes a stink

Biden

Pharmalot By Ed Silverman

U.S. will back proposal to waive intellectual property rights and boost Covid-19 vaccine production

Porous Silica Nanoparticles

Biotech By Elizabeth Cooney

How nanotechnology helps mRNA Covid-19 vaccines work

Magnifying glass

Pharma By Ed Silverman

WHO, international regulatory group urge pharma to publish clinical study reports

All Coverage

Pharmalot By Ed Silverman

Pharmalittle: U.K. says IP waiver is insufficient for Covid-19 vaccine access; EU sues AstraZeneca over vaccine supply — again

Pharmalot Coming/Going STILL

Pharmalot By Ed Silverman

Up and down the ladder: The latest comings and goings

advertisement

Pharmalot By Ed Silverman

Pharmalittle: Pfizer seeks full FDA approval for its Covid-19 shot; EU is willing to explore Covid-19 IP waiver

Painkillers

Pharmalot By Ed Silverman

Massachusetts sues Publicis for designing ‘marketing schemes’ to boost OxyContin sales

vaccine silhouette

Pharmalot By Ed Silverman

The U.S. opened pandora’s box on IP waivers for Covid-19 vaccines. What happens now?

Clinical Trials illo

Pharmalot By Ed Silverman

In Belgium, too many clinical trial sponsors waffle about reporting required results

Pharmalot By Ed Silverman

Pharmalittle: Biden supports WTO proposal on Covid-19 vaccine IP; Biogen Alzheimer’s drug is cost-effective at $2,500

money ladders

Pharmalot By Ed Silverman

Incyte pays $12.6 million to resolve claims it paid drug kickbacks through charity

Cambridge: Biogen

Pharmalot By Ed Silverman

Biogen’s Alzheimer’s drug may only be cost effective at $2,500 a year

Pharmalot By Ed Silverman

Pharmalittle: Pharma showers a key Democratic senator with cash; Lilly exec accused of altering factory documents

Pill Dollars

Pharmalot By Ed Silverman

Rising wholesale drug prices really do matter to half of all commercially insured Americans

Pharmalot By Ed Silverman

Pharmalittle: Pfizer Covid-19 vaccine to generate $26 billion in 2021 sales; EMA reviews Sinovac Covid-19 vaccine

Gilead office remdesivir

Pharmalot By Ed Silverman

Gilead sues Russia over a compulsory license issued to a company making remdesivir

drugs

Pharmalot By Ed Silverman

European Commission fines a Merck KGaA unit for providing misleading info prior to a merger

Pharmalot By Ed Silverman

Pharmalittle: U.S. trade rep to talk with WTO about IP and Covid-19 vaccines; WHO’s Tedros plans to seek re-election

capped vials

Pharmalot By Ed Silverman

Brazilian senate votes to suspend patents in bid to widen access to Covid-19 vaccines

Pharmalot Coming/Going STILL

Pharmalot By Ed Silverman

Up and down the ladder: The latest comings and goings

Pharmalot By Ed Silverman

Pharmalittle: Wyden goes back to the drawing board on drug pricing; Emergent undergoes an executive shake-up

Humira

Pharmalot By Ed Silverman

Did someone say patent thicket? AbbVie CEO to testify before Congress about drug pricing tactics

Rising Drug Cost

Pharmalot By Ed Silverman

Global spending on medicines could hit $1.6 trillion by 2025 — and that doesn’t include Covid-19 vaccines

Pharmalot By Ed Silverman

Pharmalittle: Biden issues ’empty call’ for drug pricing reform; FDA threatens to fine company for not posting trial results

pill shopping cart

Pharmalot By Ed Silverman

Americans paid two to four times as much for some drugs as in three other countries

Karen Howley

Pharmalot By Ed Silverman

For the first time, the FDA may fine a drug maker for failing to post clinical trial results

Pharmalot By Ed Silverman

Pharmalittle: Pfizer Covid-19 pill could be ready by year-end; Warren urges SEC to probe Emergent CEO over stock sales